๐Ÿ‡ฎ๐Ÿ‡ชIreland
16ยฐC Partly Cloudy ยท Dublin
Live Updates
--:--:-- IST
Writer Login
Latest
Priya Life Science Clinical trial register
TrackersDrugsComparisonsAPI
Trackers› Clinical trials› Shanghai
Clinical trial register · China

Clinical Trials in Shanghai, 2026

Every study on the ClinicalTrials.gov registry that lists a site in China and is open, about to open, active-but-closed, or enrolling by invitation. Filter it, cite it, and take it away as a file.

Download CSV
Source: ClinicalTrials.gov, U.S. National Library of Medicine. Complete coverage โ€” all 19052 matching records held by the registry are in this view. Synced 22 Sep 2026, 11:10 UTC
19052
Studies in scope
all four open statuses
11786
Recruiting now
open to new participants
2009
Lead sponsors
across recruiting studies
Top sites
Shanghai 53 Hefei 3 Zunyi 2 Ningbo 2 Changchun 2
Narrow the registerReset
Recruitment status
Phase
Lead sponsor
Fudan University454 Ruijin Hospital276 Shanghai Zhongshan Hospital163 RenJi Hospital135 Children's Hospital of Fudan University84 Clear sponsor filter
Site location
Shanghai53 Hefei3 Zunyi2 Ningbo2 Changchun2
All 32 locations
Target enrolment
to

Trials with a site in Shanghai

53 of 19052 studies
Download
Status
Study
Lead sponsor
Phase
Enrol
Chinese sites
Start
Recruiting
T2AIR: Real-World Efficacy and Safety of Biologics Targeting Type 2 Inflammation in Asthma and COPD
NCT07823842Asthma, COPD (Chronic Obstructive Pulmonary Disease)
Shanghai Pulmonary Hospital, Shanghai, China
Observational
538
Shanghai
2026-07-30
Recruiting
Oral Paclitaxel Solution With Immunotherapy and Concurrent SBRT as Neoadjuvant Treatment for Older Adults With NSCLC
NCT07754812NSCLC (Non-small Cell Lung Cancer)
DrugPaclitaxel
Shanghai Pulmonary Hospital, Shanghai, China
Phase 4
78
Guangzhou, Suqian, Shanghai, Hangzhou, Lishui
2026-06-25
Not yet open
Application of Electromagnetic Navigation System in Pulmonary Nodule Localization
NCT07595120Pulmonary Nodules, Early-Stage Lung Cancer
Shanghai Pulmonary Hospital, Shanghai, China
Not applicable
400
Shanghai
2026-05
Not yet open
A Clinical Trial on the Outcomes of Comprehensive Enhanced Prophylaxis Management (CEPM) in Chinese Patients With EGFR-Mutated Advanced NSCLC Receiving Amivantamab-Based Regimens
NCT07469488NSCLC (Advanced Non-small Cell Lung Cancer), VTE (Venous Thromboembolism), Rash Due to Epidermal Growth Factor Receptor Inhibitors, Infusion Reaction
Shanghai Pulmonary Hospital, Shanghai, China
Phase 4
122
Shanghai
2026-04-30
Not yet open
Combining Furmonertinib With Local Therapy for Inoperable Early-stage Lung Cancer: A Phase II Trial
NCT07517640Non-small Cell Lung Cancer
DrugFurmonertinib
Shanghai Pulmonary Hospital, Shanghai, China
Phase 2
45
Shanghai
2026-04-01
Not yet open
TEAS for Ipsilateral Shoulder Pain After Video-Assisted Thoracoscopic Lung Surgery
NCT07494591Ipsilateral Shoulder Pain, Video-Assisted Thoracoscopic Surgery
Shanghai Pulmonary Hospital, Shanghai, China
Not applicable
216
Shanghai
2026-04-01
Not yet open
Study on the Efficacy and Safety of JSKN016 as Neoadjuvant Therapy in Resectable Stage II-III Non-small Cell Lung Cancer Patients
NCT07493980NSCLC Stage II
DrugsJSKN016·Carboplatin·Tislelizumab
Shanghai Pulmonary Hospital, Shanghai, China
Phase 2
54
Shanghai
2026-03
Not yet open
Acetohydroxamic Acid Combined With a Short-Course Regimen for MDR-TB (AHA-PLUS)
NCT07393438Multidrug-Resistant Tuberculosis, Rifampicin-resistant Tuberculosis, MDR-TB, RR-TB
Shanghai Pulmonary Hospital, Shanghai, China
Phase 2
120
Hefei, Shanghai
2026-02-21
Not yet open
A Multi-modal Integrating Imaging and Cell-free DNA Methylation in Lung Cancer Early Detection (CMe-Lung): a Multi-center, Observational Study
NCT07375979Lung Cancer
Shanghai Pulmonary Hospital, Shanghai, China
Observational
14,300
Shijiazhuang, Zhengzhou, Changchun, Shenyang, Shanghai, Kunming
2026-02-05
Not yet open
Intrapleural Bupivacaine Analgesia for Postoperative Pain Management After Minimally Invasive Video-Assisted Thoracoscopic Surgery: A Randomized Controlled Trial
NCT07393386Pain Management
DrugBupivacaine
Shanghai Pulmonary Hospital, Shanghai, China
Phase 4
249
Shanghai
2026-02-01
Recruiting
Efficacy of Anti-CTLA-4 Antibody Combined With Sintilimab and Chemotherapy as Neoadjuvant Therapy for Resectable Stage II-III Non-Small Cell Lung Cancer
NCT07410975NSCLC Stage II, NSCLC Stage III
DrugsIpilimumab N01·Tislelizumab
Shanghai Pulmonary Hospital, Shanghai, China
Phase 2
54
Shanghai
2026-01-10
Recruiting
Inspiratory Flow Rate Capability in Pulmonary Fibrosis Patients
NCT07820254Idiopathic Pulmonary Fibrosis, Progressive Pulmonary Fibrosis
Shanghai Pulmonary Hospital, Shanghai, China
Observational
60
Shanghai
2026-01-10
Recruiting
IBI363 (PD-1/IL-2ฮฑ-bias) in Combination With Chemotherapy as Neoadjuvant Therapy in Initially Unresectable Stage III Non-Small Cell Lung Cancer
NCT07408635Unresectable Stage III Non-small Cell Lung Cancer, Carcinoma, Non-Small-Cell Lung Cancer (NSCLC)
Shanghai Pulmonary Hospital, Shanghai, China
Phase 2
43
Shanghai
2026-01-07
Recruiting
Neoadjuvant Sacituzumab Tirumotecan and Limertinib for Potentially Resectable Stage โ…ข EGFR-mutant Non-small Cell Lung Cancer
NCT07323056EGFR-mutant Non-small Cell Lung Cancer, Potentially Resectable
Shanghai Pulmonary Hospital, Shanghai, China
Phase 2
36
Shanghai
2026-01-01
Recruiting
Impact of Sugammadex Versus Neostigmine on Early Postoperative Pulmonary Function
NCT07309393Residual Neuromuscular Block
DrugNeostigmine
Shanghai Pulmonary Hospital, Shanghai, China
Not applicable
240
Shanghai
2025-12-30
Recruiting
Synthetic PET From CT Improves Precision Diagnosis and Treatment of Lung Cancer: a Prospective, Observational, Multicenter Study
NCT07243873Lung Cancer, PET-CT
Shanghai Pulmonary Hospital, Shanghai, China
Observational
10,000
Zunyi, Jiangxi, Shanghai, Ningbo
2025-12-01
Not yet open
Segmentectomy vs Lobectomy for 2 - 3cm IASLC Grade 1-2 Lung Adenocarcinoma: A Multi-center RCT
NCT07169903Lung Adenocarcinoma
Shanghai Pulmonary Hospital, Shanghai, China
Phase 3
587
Shanghai
2025-10-01
Not yet open
Efficacy and Safety of Huanjingjian Decoction in Women With Premature Ovarian Insufficiency
NCT07020429Premature Ovarian Insufficiency
Shanghai Pulmonary Hospital, Shanghai, China
Not applicable
276
Shanghai
2025-09-01
Recruiting
Thoracic Surgery Intercostal Block Trial With Liposomal vs. Hydrochloride Bupivacaine
NCT07134660Postoperative Pain, Acute, Lung Cancer
Shanghai Pulmonary Hospital, Shanghai, China
Not applicable
210
Shanghai
2025-09-01
Not yet open
A Prospective, Multicenter Clinical Study of Hetrombopag in the Prevention of Thrombocytopenia Caused by Lung Cancer Therapy
NCT07101627Lung Cancer
DrugHetrombopag
Shanghai Pulmonary Hospital, Shanghai, China
Phase 2
149
Nanjing, Shanghai
2025-08-01
Not yet open
Toripalimab Combined With Chemotherapy as Adjuvant Therapy for Incidental Small Cell Lung Cancer After Radical Resection of Lung Cancer: A Single-Center, Randomized Controlled Clinical Study Protocol Number: LungMate-033
NCT07097948Postoperative Incidental Small Cell Lung Cancer, Toripalimab Adjuvant Therapy Evaluation
DrugsEtoposide·Tislelizumab
Shanghai Pulmonary Hospital, Shanghai, China
Phase 2
40
Shanghai
2025-08
Recruiting
Neoadjuvant Sugemalimab + Chemotherapy Followed by Adjuvant Sugemalimab for Patients With Resectable Stage II-IIIA Non-small-cell Lung Cancer Patients
NCT06987734Lung Cancer (NSCLC)
Shanghai Pulmonary Hospital, Shanghai, China
Phase 2
25
Shanghai
2025-06-19
Recruiting
The C-BRIDGE Study: China Bronchiectasis Research Involving Databases, Genomics, and Endotyping
NCT06900062Bronchiectasis Adult
Shanghai Pulmonary Hospital, Shanghai, China
Observational
1,500
Guiyang, Changchun, Jinan, Shanghai, Jiaxing
2025-04-06
Not yet open
Neoadjuvant Chemotherapy Combined With Bispecific Antibody Versus Monoclonal Antibody in Locally Advanced NSCLC
NCT06837948Locally Advanced Non-Small Cell Lung Cancer
DrugsPumitamig·Nab-paclitaxel·Carboplatin·Tislelizumab
Shanghai Pulmonary Hospital, Shanghai, China
Phase 2
160
Shanghai
2025-02-18
Recruiting
Post-line Treatment With Teniposide for c-Myc-driven Extensive-stage Small Cell Lung Cancer
NCT06758700Extensive-stage Small Cell Lung Cancer (ES-SCLC), Thoracic Neoplasms, Lung Neoplasms, Lung Diseases
Shanghai Pulmonary Hospital, Shanghai, China
Phase 2
15
Shanghai
2025-02-07
By invitation
The Effect of Semi-recumbent Position on Hypoxemia After Lung Segment/Lobe Surgery
NCT07060625Lung Cancer (Diagnosis), Hypoxemia
Shanghai Pulmonary Hospital, Shanghai, China
Observational
308
Shanghai
2024-12-23
Recruiting
An Exploratory Study of Tislelizumab in Combination with Chemotherapy in Immuno-experienced Patients with EGFR/ALK/ROS1-negative Advanced NSCLC in the Second-line Setting
NCT06749886Lung Cancer
DrugsDenosumab·Paclitaxel·Tislelizumab
Shanghai Pulmonary Hospital, Shanghai, China
Phase 2
22
Shanghai
2024-11-19
Not yet open
Toripalimab and JS004 Combined With Platinum-based Chemotherapy for Relapsed and Extensive-stage Small Cell Lung Cancer
NCT06648200Small Cell Lung Cancer Extensive Stage, Small Cell Lung Cancer Recurrent
Shanghai Pulmonary Hospital, Shanghai, China
Phase 2
100
Shanghai
2024-11-01
Active, closed
Neoadjuvant Sunvozertinib in Stage II-IIIB Non-small Cell Lung Cancer Harboring EGFR Exon 20 Insertion Mutation.
NCT07274761Potentially Resectable EGFR Exon 20 Insertion Non-Small Cell Lung Cancer, Non Small Cell Lung Cancer
DrugSunvozertinib
Shanghai Pulmonary Hospital, Shanghai, China
Phase 2
24
Shanghai
2024-10-17
Not yet open
A Clinical Trial of Furmonertinib Combination Therapy As Neoadjuvant Treatment in Resectable EGFR-Mutated NSCLC
NCT06585644Lung Cancer (NSCLC)
Shanghai Pulmonary Hospital, Shanghai, China
Phase 2
44
Shanghai
2024-10-01
Not yet open
Efficacy of PD-1 Inhibitor Combination Therapy in Non-small Cell Lung Cancer Patients Who Have Not Achieved Major Pathologic Response After Neoadjuvant Immunotherapy: a Multicenter, Phase II Clinical Trial
NCT06620822Non Small Cell Lung Cancer
Shanghai Pulmonary Hospital, Shanghai, China
Phase 2
296
Shanghai
2024-09-30
Recruiting
A Study on the Efficacy of Atezolizumab Combined with Chemotherapy
NCT06780826Lung Cancer, Small Cell
Shanghai Pulmonary Hospital, Shanghai, China
Observational
1,430
Shanghai
2024-08-28
Recruiting
Adjuvant Benmelstobart for Stage IB, Grade 3 Invasive Lung Adenocarcinoma
NCT06528847Non-Small Cell Lung Cancer
DrugEtoposide
Shanghai Pulmonary Hospital, Shanghai, China
Phase 2
62
Shanghai
2024-06-05
Active, closed
Toripalimab Combined With SBRT for NSCLC
NCT06293690Non-small Lung Cancer
Shanghai Pulmonary Hospital, Shanghai, China
Phase 2
40
Shanghai
2024-04-15
Recruiting
Neoadjuvant Therapy With Toripalimab and JS004 Combined With Etoposide and Platinum Chemotherapy for Limited-stage Small Cell Lung Cancer : A Phase 2 Trial
NCT06256237Limited Stage Small Cell Lung Cancer
Shanghai Pulmonary Hospital, Shanghai, China
Phase 2
30
Shanghai
2024-04-01
Recruiting
Disitamab Vedotin in Combination with Tislelizumab and Bevacizumab in a Phase II Clinical Study of Locally Advanced or Metastatic Non-small Cell Lung Cancer with HER2 Mutation/amplification/expression
NCT06749860Lung Cancer
DrugsDisitamab Vedotin·Bevacizumab·Tislelizumab
Shanghai Pulmonary Hospital, Shanghai, China
Phase 2
58
Shanghai
2024-02-02
Not yet open
Perioperative Immunotherpay Versus Adjuvant Immunotherapy for Resectable Non-small Cell Lung Cancer
NCT06109402Stage II-IIIB(N2) Non-small Cell Lung Cancer
DrugsEtoposide·Nab-paclitaxel·Pemetrexed·Carboplatin
Shanghai Pulmonary Hospital, Shanghai, China
Phase 2
160
Shanghai
2023-12-20
Recruiting
Exploring the Frontiers of Neoadjuvant Therapy for Lung Cancer: a Prospective Observational Real-world Study
NCT06216782Lung Cancer
Shanghai Pulmonary Hospital, Shanghai, China
Observational
2,000
Shanghai
2023-12-16
Recruiting
Patient-derived Tumor-like Cell Cluster Model-based Precision Treatment Strategy on Non-small Cell Lung Cancer
NCT07328945Non-small Cell Lung Cancer
Shanghai Pulmonary Hospital, Shanghai, China
Observational
250
Shanghai
2023-12-01
Recruiting
Robot-assisted vs VATS for Thymoma
NCT06029621Thymoma
Shanghai Pulmonary Hospital, Shanghai, China
Not applicable
304
Shanghai, Zhejiang
2023-11-20
Recruiting
Neoadjuvant Treatment For Locally Advanced Thymic Cancer
NCT06019468Thymic Carcinoma
Shanghai Pulmonary Hospital, Shanghai, China
Phase 2
25
Shanghai
2023-11-04
Recruiting
Exploration on the Value of MRD Based on ctDNA Detection in Predicting Recurrence of Resected Non-small Cell Lung Cancer
NCT05965024Non-small Cell Lung Cancer
Shanghai Pulmonary Hospital, Shanghai, China
Observational
377
Shanghai
2023-10-25
Recruiting
Exploring the Neo-Adjuvant Therapy Effects on Lung Cancer Through Monitoring and Assessment of Tumor Environment
NCT05857800Lung Cancer
Shanghai Pulmonary Hospital, Shanghai, China
Observational
2,000
Shanghai
2023-05-25
Recruiting
Drug Exposure and Minimum Inhibitory Concentration in the Treatment of MAC Lung Disease
NCT05824988Mycobacterium Avium Complex, Mycobacterium Avium-Intracellulare Infection, Gram-Positive Bacterial Infections, Mycobacterium Infections
Shanghai Pulmonary Hospital, Shanghai, China
Observational
100
Shanghai
2023-04-14
Recruiting
Induction Therapy With PD-1 Antibody Combined With Platinum-based Doublet Chemotherapy for Locally-advanced Non-small Cell Lung Cancer
NCT05766800Locally Advanced, Non-small Cell Lung Cancer
DrugsLiposomal paclitaxel·Serplulimab·Nab-paclitaxel·Pemetrexed
Shanghai Pulmonary Hospital, Shanghai, China
Phase 2
100
Shanghai
2023-03-14
Recruiting
Neoadjuvant Immunotherapy for Stage III Non-small Cell Lung Cancer
NCT04728724Non-small Cell Lung Cancer Stage III
DrugTislelizumab
Shanghai Pulmonary Hospital, Shanghai, China
Phase 2
100
Shanghai
2022-09-10
Recruiting
A Exploratory Study of Vฮณ2Vฮด2 T Lymphocyte-based Immunotherapy for MDR-TB
NCT05493267MDR-TB, Immunotherapy
Shanghai Pulmonary Hospital, Shanghai, China
Phase 4
30
Shanghai
2022-08-03
Recruiting
Neoadjuvant Furmonertinib Plus Bevacizumab or Furmonertinib Monotherapy for Resectable and Potentially Resectable Stage III-IVA EGFR Mutation-Positive Lung Adenocarcinoma
NCT05503667Lung Adenocarcinoma Stage III, Lung Adenocarcinoma Stage IV, EGFR Gene Mutation
Shanghai Pulmonary Hospital, Shanghai, China
Phase 2
96
Shanghai
2022-02-01
Active, closed
Neoadjuvant HS-10296 (Almonertinib) Therapy for Potential Resectable Stage III EGFR Mutation-Positive Non-small Cell Lung Cancer
NCT04685070Non-small Cell Lung Cancer Stage III
DrugAlmonertinib
Shanghai Pulmonary Hospital, Shanghai, China
Phase 2
56
Shanghai
2021-12-14
Recruiting
Efficiency and Safety of Microwave Ablation Plus Immune Checkpoint Inhibitor for Patients With Multiple Primary Lung Cancer: A Open, Multi-center, Phase II Clinical Trial
NCT05053802Multiple Primary Lung Cancer
Shanghai Pulmonary Hospital, Shanghai, China
Phase 2
146
Shanghai
2021-03-21
Recruiting
PD-L1 Antibody (TQB2450) Plus Chemotherapy for Previously Untreated Limited- Stage Small-cell Lung Cancer
NCT04539977Small-cell Lung Cancer
DrugsEtoposide·Carboplatin
Shanghai Pulmonary Hospital, Shanghai, China
Phase 2
40
Shanghai
2020-09-01
Recruiting
Segmentectomy Versus Lobectomy for Lung Adenocarcinoma โ‰ค 2cm
NCT04937283Lung Adenocarcinoma
Shanghai Pulmonary Hospital, Shanghai, China
Not applicable
690
Hefei, Nanyang, Nantong, Xuzhou, Yancheng, Jinan, Shanghai, Hangzhou
2019-10-01
Recruiting
Surgery With or Without Chemotherapy for Stage I NSCLC With Micropapillary Component โ‰ฅ 20%
NCT03351842Chemotherapy, Adjuvant, Lung Adenocarcinoma, Stage I, Treatment, Histological Type of Neoplasm
Shanghai Pulmonary Hospital, Shanghai, China
Phase 2
460
Shanghai
2017-09-01
Rows per page Showing 1–53 of 53
1
Cite this view

Priya Life Science (2026). Clinical trial register: studies with a Chinese investigative site, filtered. Derived from ClinicalTrials.gov. Retrieved 25 September 2026. https://priyalifescience.com/clinical-trials-china/city/shanghai

Query this register directly
GET /api/trials?country=cn&status=recruiting&format=json Try it now →

About this register

This register is built from ClinicalTrials.gov, the trial registry run by the U.S. National Library of Medicine. It includes every study on the registry that lists at least one investigative site in China and is recruiting, not yet recruiting, active but no longer recruiting, or enrolling by invitation: 19,052 studies in total at the last sync on 22 Sep 2026, 11:10 UTC. The full list can be downloaded as CSV or queried as JSON through the register API.

This page shows the 53 of those studies with a site in Shanghai that also match the filters currently applied.

How many clinical trials are recruiting in Shanghai?

32 of the 53 studies on this page are recruiting new participants as of the 22 Sep 2026, 11:10 UTC sync. A further 17 have not yet opened recruitment, 3 are active but closed to new participants, and 1 are enrolling by invitation only. Eligibility for any study is decided by its study team.

Summary by phase

Studies by phase (Shanghai), 53 studies
PhaseStudiesRecruitingShare
Phase 2291654.7%
Observational121022.6%
Not applicable7413.2%
Phase 4427.5%
Phase 3101.9%

Most active sponsors

Lead sponsors with the most studies (Shanghai)
Lead sponsorStudiesRecruiting
Shanghai Pulmonary Hospital, Shanghai, China5332
Listing here is informational and not medical advice; eligibility is determined by each study team. See also the Ireland, UK, EU, USA and India registers.